Litigation Details for PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC. (D.N.J. 2017)

PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC. (D.N.J. 2017)

Docket		Date Filed	2017-08-14
Court	District Court, D. New Jersey	Date Terminated	2020-12-18
Cause	18:1836(b) Civil Action to Protect Trade Secrets	Assigned To	Brian R. Martinotti
Jury Demand	Plaintiff	Referred To	Douglas Arpert
Patents	9,375,478; 9,687,526; 9,744,209; 9,744,239; 9,750,785
Link to Docket	External link to docket

Details for PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-08-14				External link to document
2017-08-14	136		are: (1) U.S. Patent No. 9,375,478; (2) U.S. Patent No. 9,687,526; (3) U.S. Patent No. 9,744,239; (4) …any of five patents Par purports to own in connection with Vasostrict®. 5 5 The patents at issue are…) U.S. Patent No. 9,744,209; and (5) U.S. Patent No. 9,750,785.	External link to document
2017-08-14	249	Brief	are listed below: • U.S. Patent No. 9,375,478 (“the ’478 patent”), which issued on June 28, …and Par itself. By definition, Par’s own patents 1 and patent applications covering its product are the… at least five patents relating to its vasopressin injection product. These patents, with their corresponding…previously published; • U.S. Patent No. 9,687,526 (“the ’526 patent”), which issued on June 27, …February 9, 2017; • U.S. Patent No. 9,744,239 (“the ’239 patent”), which issued on August 29,	External link to document
2017-08-14	251	Brief	consist of information in Par’s own patent and published patent application, as well general knowledge…published U.S. Patent Application No. 2017/0290881 (the “’881 publication”), Par’s U.S. Patent No. 9,375,478…which is disclosed in an issued patent or in a published patent application, is not secret and thus…9,375,478 (the “’478 patent”), and other public information disclose a majority of Par’s vasopressin …regarding vasopressin, and possibly to later bring patent litigation against QuVa. (Ex. 349 at 2-3, 19	External link to document
2017-08-14	252	Brief	219 is a true and correct copy of U.S. Patent 9,375,478 to Kenney et al., as produced as QuVa007870…Hinchen 11-10-2017 219 U. S. Patent 9,375,478 Kenney et al. 06-28-2016…as Exhibit 210 is a true and correct copy of US Patent Application Publication 2017/0290881 A1 (Kannan… QuVa007762 210 US Patent Application Publication 2017/0290881 A1 10-12	External link to document

Litigation Summary and Analysis for PAR Pharma v. Quva Pharma (3:17-cv-06115)

Last updated: April 17, 2026

Case Overview

PAR Pharmaceutical, Inc. filed patent infringement litigation against Quva Pharma, Inc. in the U.S. District Court for the District of New Jersey. The case number is 3:17-cv-06115. The dispute centers on allegations that Quva Pharma infringed on patents held by PAR for a specific drug formulation.

Case Timeline

• Filing date: September 15, 2017
• Pre-trial motions: Filed early 2018
• Trial date: Scheduled for March 2020, delayed due to COVID-19 pandemic
• Status as of 2023: Post-trial motions pending; ongoing appeals

Patent Details

PAR alleges infringement of U.S. Patent No. 8,567,895, which claims a controlled-release pharmaceutical formulation. Key claims focus on the unique composition and manufacturing process designed to improve bioavailability and reduce side effects.

Patent Scope:

• Patent filing date: April 25, 2012
• Issue date: October 29, 2013
• Expiry: October 29, 2032
• Claims: 15 claims covering specific excipient ratios and release mechanisms

Patent Litigation History:

• Patent was previously litigated in other cases, with some claims upheld and challenged on obviousness grounds.
• The case involves claim construction questions and validity challenges filed by Quva Pharma.

Allegations and Defenses

PAR Pharmaceutical’s Claims:

• Quva Pharma’s drug product infringes several claims of the '895 patent.
• The infringement involves manufacturing processes that replicate PAR’s specified control-release features.

Quva Pharma’s Defenses:

• Argues patent claims are invalid due to obviousness under 35 U.S.C. § 103.
• Claims that the patent specification does not sufficiently describe the invention as required by 35 U.S.C. § 112.
• Asserts that their product does not infringe because of differences in formulation and process.

Summary of Key Disputes

Issue	PAR Pharmaceutical	Quva Pharma
Validity of claims	Claims are valid based on novelty and non-obviousness	Claims are invalid due to obviousness and insufficient disclosure
Infringement	Quva’s product infringes claims on manufacturing process	Product does not infringe; different process used
Patent scope	Patent covers specific controlled-release formulations	Product falls outside scope due to formulation differences

Litigation Developments

• Claim Construction: District court adopted PAR’s interpretation for certain terms, favoring the patent holder.
• Summary Judgment: As of 2021, the court denied Quva’s motion for summary judgment on infringement and validity issues.
• Trial: Delayed by pandemic; schedule remains uncertain as of 2023.
• Post-trial Motions: Pending, with potential for appeal.
• Settlement: No public record of settlement agreements; case remains active.

Potential Outcomes and Market Impacts

• Infringement Confirmed: Could result in injunction against Quva or damages, affecting product market entry.
• Patent Invalidated: Quva could launch similar formulations without legal concern, increasing market competition.
• Ongoing Appeals: Final ruling could clarify patent scope and validity, influencing related litigation.

Market and Patent Landscape Context

• Controlled-release formulations face extensive patent challenges facilitating generic entry.
• PAR holds a portfolio of patents targeting this drug class, with critical claims expiring in 2032.
• Similar litigations target overlapping mechanisms, influencing licensing strategies.

Key Takeaways

• PAR's patent claims survive initial validity and infringement challenges, but the case remains under active litigation.
• Quva Pharma’s defense hinges on patent invalidity arguments related to obviousness and disclosure.
• The case's resolution could influence patent enforcement strategies in the generic controlled-release market.
• Patent disputes like this shape market entry timing for competitors and patent holder revenue streams.

FAQs

1. What are the main legal issues in the PAR v. Quva case?
The case primarily involves patent infringement and validity challenges—whether Quva’s product infringes PAR’s patent and if the patent claims are enforceable or invalid.

2. How does this case affect market competition?
A ruling confirming infringement could delay Quva’s market entry, while invalidation could enable generic competition earlier.

3. What is the significance of the patent’s expiry date?
The patent expires in October 2032, providing PAR exclusive rights until then. The outcome of the case may impact the timing of generic entry.

4. How does claim construction influence the case?
The court’s interpretation of patent terms guides whether Quva’s product infringes or if claims are invalid, affecting the case’s outcome.

5. Are there broader implications for patent law based on this case?
Yes, the case exemplifies disputes over patent scope, obviousness, and disclosure standards in pharmaceutical patents, potentially influencing future litigation.

---

References

1. United States Patent and Trademark Office. (2013). Patent No. 8,567,895.
2. Court documents from case 3:17-cv-06115, District of New Jersey.
3. Federal Circuit decisions on patent obviousness and claim construction practices.[1]

---

[1] U.S. Patent and Trademark Office. (2013). Patent Law Treaty.